https://www.selleckchem.com/products/inf195.html
The results showed that 5% and 10% Kolliphor® HS·15 increased the bioavailability of PTH(1-34) to 14.76% and 30.87%, respectively. In conclusion, an effective and biosafe PTH(1-34) intranasal formulation was developed by using 10% Kolliphor® HS·15 as a permeation enhancer. Intranasal formulations with higher concentrations of Kolliphor® HS·15 for higher bioavailability of PTH(1-34) could be further researched.In this study, 38 nm-sized and flake-like-shaped CuO NPs (10, 50, 100, 150 μg/10 µl/larva) were force-fed to fourth instar (100 ±
Curtir
Comentario
Compartilhar
